rs4784165 — TOX3 TOX3 rs4784165

TOX3 rs4784165 — The PCOS Susceptibility Locus Linking Transcriptional Regulation

to Insulin Resistance

Polycystic ovary syndrome (PCOS) affects 5–15% of women of reproductive age worldwide and is the leading cause of anovulatory infertility. Beyond its reproductive features — irregular cycles, excess androgens, and polycystic ovaries — PCOS is fundamentally a metabolic disorder: 50–70% of affected women have insulin resistance, independent of body weight. Genome-wide association studies in Han Chinese women have identified over a dozen PCOS susceptibility loci, and among them rs4784165 near the TOX3 gene¹¹ rs4784165 near the TOX3 gene
TOX3: TOX High Mobility Group Box Family Member 3, chromosome 16q12.1 stands out for its specific link to the metabolic rather than purely hormonal features of the syndrome.

The Mechanism

TOX3²² TOX3
a high-mobility-group (HMG) box transcription factor originally characterized in neurons encodes a protein that regulates calcium-dependent gene transcription. TOX3 interacts with CREB (cAMP response element- binding protein) and CBP (CREB-binding protein), and knockdown of endogenous TOX3 substantially reduces calcium-induced gene expression. In addition to its neuronal role, emerging evidence places TOX3 in hepatic metabolic regulation: studies suggest TOX3 controls hepatic gluconeogenesis and insulin sensitivity through hepatic transcriptional programs, and that dysregulation of TOX3 exacerbates insulin resistance and glucose intolerance — mechanisms central to both type 2 diabetes and PCOS pathogenesis.

The rs4784165 variant sits in an intronic region of a long non-coding RNA locus (LOC107984901) on chromosome 16q12.1, approximately adjacent to the TOX3 gene. No pathogenic coding mutations have been found in TOX3 in PCOS women, confirming that rs4784165 acts as a regulatory signal³³ rs4784165 acts as a regulatory signal
sequencing of all TOX3 exons and exon-intron boundaries in 200 Han Chinese PCOS women found no pathogenic variants, PMID 25311971 rather than a structural variant. Epigenetic data support this interpretation: Ning et al. 2017 (30 PCOS/30 controls)⁴⁴ Ning et al. 2017 (30 PCOS/30 controls)
European Review for Medical and Pharmacological Sciences found significantly lower TOX3 promoter methylation in PCOS granular cells and serum, leading to reduced TOX3 protein expression — suggesting the variant alters local chromatin accessibility or regulatory element activity near this locus.

The Evidence

The TOX3 rs4784165 G allele was first identified as a PCOS risk allele in a second Han Chinese genome-wide association study by Shi et al. 2012⁵⁵ second Han Chinese genome-wide association study by Shi et al. 2012
Nature Genetics; 1,510 cases and 2,016 controls discovery + independent replication, one of eight newly discovered PCOS loci. The GWAS odds ratio for G allele carriers is approximately 1.15, a modest but consistently replicated effect. A meta-analysis across 47 studies (10,584 PCOS cases, 16,150 controls) estimated OR = 1.08 (95% CI: 1.00–1.16) for PCOS susceptibility.

The clinical significance of this locus extends beyond simple disease susceptibility to metabolic stratification within PCOS. Tian et al. 2020 (2,082 Han Chinese PCOS women)⁶⁶ Tian et al. 2020 (2,082 Han Chinese PCOS women)
Frontiers in Endocrinology found that women carrying at least one G allele (GG + GT) had significantly higher rates of insulin resistance than TT homozygotes (53.3% vs. 48.5%, P = 0.027, OR = 1.27) after adjustment for age and BMI — a dominant model effect. The G allele was also associated with elevated TG/HDL-C ratios, a key atherogenic marker. Across populations, the G allele frequency varies substantially: ~25% in Europeans, ~33% in East Asians, and ~42% in Africans.

In a Saudi Arabian cohort, Bakhashab & Ahmed 2019 (94 PCOS cases, 94 controls)⁷⁷ Bakhashab & Ahmed 2019 (94 PCOS cases, 94 controls)
Bioinformation found significant association between rs4784165 and the combined oligo/amenorrhea plus polycystic ovarian morphology PCOS subgroup, linking this variant to the ovarian structural features of the syndrome as well as metabolic features. Notably, replication of this locus in European populations has not been conclusively demonstrated, suggesting either ethnic-specific genetic architecture or insufficient power in available European cohorts.

Practical Actions

For G allele carriers with PCOS or PCOS-adjacent features (irregular cycles, elevated androgens, insulin resistance), the dominant model association with insulin resistance is the most actionable finding. Insulin resistance in PCOS is independently addressable through genotype-informed supplementation: myo-inositol (the glucose-transporter-linked signaling molecule) at 2–4 g/day has the strongest evidence base for improving insulin sensitivity, ovarian function, and androgen levels specifically in PCOS women with insulin resistance — effects that are more pronounced in those with documented IR at baseline.

Fasting insulin and HOMA-IR monitoring — ideally annually for GG homozygotes — provides the earliest signal of progressing insulin resistance before it affects glucose tolerance. The TG/HDL-C ratio (elevated in G allele carriers per Tian 2020) is a readily available surrogate marker for atherogenic dyslipidemia and insulin resistance that can be tracked with a standard fasting lipid panel.

Interactions

rs2479106 (DENND1A): DENND1A is the strongest GWAS-replicated PCOS locus and acts through theca cell androgen biosynthesis. TOX3 rs4784165 and DENND1A rs2479106 appear to affect PCOS through different mechanisms — androgen production vs. insulin resistance — and women carrying risk alleles at both loci may face compounding PCOS severity across both hormonal and metabolic dimensions. No compound effect study has directly examined this combination.

rs13405728 (LHCGR): The LH/hCG receptor locus affects gonadotropin sensitivity in granulosa cells. Combined risk at LHCGR (elevated LH sensitivity) and TOX3 (impaired metabolic transcriptional regulation) may represent a pathway from hypothalamic-pituitary dysregulation to ovarian dysfunction, though no published study has examined these loci jointly.